Advertisement
Canada markets close in 2 hours 27 minutes

  • S&P/TSX

    21,820.38
    +111.94 (+0.52%)
     

  • S&P 500

    4,983.94
    -27.18 (-0.54%)
     

  • DOW

    37,991.16
    +215.78 (+0.57%)
     

  • CAD/USD

    0.7277
    +0.0014 (+0.19%)
     

  • CRUDE OIL

    83.68
    +0.95 (+1.15%)
     

  • Bitcoin CAD

    88,085.73
    +893.95 (+1.03%)
     

  • CMC Crypto 200

    1,379.50
    +66.88 (+5.09%)
     

  • GOLD FUTURES

    2,414.40
    +16.40 (+0.68%)
     

  • RUSSELL 2000

    1,946.80
    +3.84 (+0.20%)
     

  • 10-Yr Bond

    4.6230
    -0.0240 (-0.52%)
     

  • NASDAQ

    15,372.56
    -228.94 (-1.47%)
     

  • VOLATILITY

    18.56
    +0.56 (+3.11%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     
MARKETS LIVE BLOG:

S&P 500 SLIPS BELOW 5,000; NASDAQ SINKS ON NETFLIX DRAG

Fed's Goolsbee says 'It makes sense to wait' before cutting rates

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KRMD, FGEN and CCXI

ACCESSWIRE
·4 min read

NEW YORK, NY / ACCESSWIRE / May 25, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Repro Med Systems, Inc. (NASDAQ:KRMD)
Investors Affected: August 4, 2020 - January 25, 2021

A class action has commenced on behalf of certain shareholders in Repro Med Systems, Inc . The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) starting in January 2020, Repro Med Systems ramped up the use of allowances, including growth rebates, to retain key customers and to incentivize growth; (2) as the rebates accrued, the Company's net sales were reasonably likely to decline; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/repro-med-systems-inc-loss-submission-form/?id=16121&from=1

ADVERTISEMENT

FibroGen, Inc. (NASDAQ:FGEN)
Investors Affected: October 18, 2017 - April 6, 2021

A class action has commenced on behalf of certain shareholders in FibroGen, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/fibrogen-inc-loss-submission-form/?id=16121&from=1

ChemoCentryx, Inc. (NASDAQ:CCXI)
Investors Affected: November 26, 2019 - May 3, 2021

A class action has commenced on behalf of certain shareholders in ChemoCentryx, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/chemocentryx-inc-loss-submission-form/?id=16121&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm



View source version on accesswire.com:
https://www.accesswire.com/648964/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-KRMD-FGEN-and-CCXI